• Tisagenlecleucel not recommended relapsed or refractory diffuse large B-cell lymphoma. (onmedica.com)
  • NICE has published final guidance which recommends tisagenlecleucel (Kymriah) therapy for use within the Cancer Drugs Fund as an option for treating relapsed or refractory diffuse large B-cell lymphoma in adults after two or more systemic therapies, only if the conditions in the managed access agreement are followed. (onmedica.com)
  • There is no standard treatment for relapsed or refractory diffuse large B-cell lymphoma after two or more systemic therapies. (onmedica.com)
  • These and other signs and symptoms may be caused by AIDS-related lymphoma or by other conditions. (genesishcs.org)
  • Sometimes AIDS-related lymphoma occurs outside the lymph nodes in the bone marrow, liver, meninges (thin membranes that cover the brain) and gastrointestinal tract. (genesishcs.org)
  • abstract = "To define the role of radiation therapy of primary orbital lymphoma, a retrospective analysis was undertaken for 18 patients with primary orbital lymphoma who were treated with curative radiotherapy between 1984 and 1995. (elsevier.com)
more